News & Events
March 04 2019

IGES Institut GmbH
Acquires Majority Shareholding in
Device Access UK

['IGES Institut GmbH\r', 'Acquires Majority Shareholding in\r', 'Device Access UK']

Berlin, March 4, 2019 (IGES Institute) – The IGES Institut GmbH today announced that it has acquired the majority of shares in the market leading U.K. reimbursement specialist company Device Access Ltd. The Southampton based consultancy provides comprehensive health economic and strategic services for international medical device manufacturers focused on launching innovative products to both the U.K. private healthcare market as well as the publicly funded National Health Service (NHS).

With this majority acquisition, the IGES Group continues its European expansion, servicing the growing global medical devices market in which Germany and the U.K. constitute core markets. The IGES Group has been active in providing consultancy services for the German medical technology market since it acquired the company AiM GmbH.

IGES Director Professor Bertram Häussler said: “U.K. is an important country for the development and application of medical devices. Furthermore, it has traditionally been seen as a European beach head for global companies to launch into Europe. The aim of this acquisition is to strengthen these connections and make them usable for all our international clients.”

Device Access founder Michael Branagan-Harris will continue to be the CEO of Device Access and will additionally lead IGES’ UK business activities as Country Manager, in order to bring the countries’ two markets closer together.

Mr. Branagan-Harris said: “Device Access and the IGES Group unite extensive knowledge of approval, market launch and reimbursement of medical devices, and their cultures fit outstandingly. The deal strengthens our respective market positions and build the potential for our growth in the European markets.”

Device Access which was established in 2010, based in Hampshire Southern England at The University of Southampton Science Park, has a large clientele of US, European and British medical device developers and a successful track record of navigating and supporting its clients into the NHS, and through 30 National Institute for Health & Care Excellence (NICE) appraisals.

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.

About IGES

The IGES Institute, founded in 1980, is the core of the IGES group. Today, it is the largest privately-owned research and consulting institution of its kind for health and infrastructure questions. IGES offers creative solutions for questions in care, quality, financing and shaping competition for all actors in the life sciences arena. Clients are government organizations, providers, NGOs and companies. The institute has conducted over 2,000 research and consulting projects since its foundation.

Further IGES Group members include the two Berlin companies CSG Clinische Studien Gesellschaft (clinical research) and IMC clinicon (analysis and consulting for hospitals), as well as HealthEcon in Basel (health economics) and AiM (analysis and consulting for medical devices) in Lörrach. In total, the IGES Group employs over 140 members of staff.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

About Device Access

Device Access UK Ltd, a privately held company was founded in 2010 and has supported Medical Device Organizations from across the world in assisting them in NHS Market Access and reimbursement strategies with a focus on gaining NICE approvals.

Device Access work closely with various NHS and UK Government bodies including the National Institute for Health and Care Excellence (NICE), The National Institute for Health Research (NIHR), and The UK Department of International Trade (DIT) in bringing new and novel Innovative medical technologies to benefit patients faster.

Since 2014 they have held a commercial Licence with NHS Digital to interrogate patient claims data to examine and understand current NHS patient treatment pathways, and are an approved NICE MedTech Early Technology Assessment (NICE MetaTOOL®) facilitator.


IGES Institut GmbH
Sandra Jessel
Press officer
Tel.: +49 (0)30 23 08 09 411

Device Access UK Ltd
Amanda Hayhurst
Gloucester Road Communications Ltd
Tel.: +44 (0) 7720 205581

Image of IGES Building Copyright

Most recent
Device Access welcomes Dr. Christopher Pomfrett to the team
February 03 2022
The Benefits and Opportunities of Entering the UK Healthcare Market with MedTech Post-Brexit
July 31 2021
NHS England Announce New Funding Mechanism for Innovative MedTech
January 27 2021
How Changes in NHS Funding May Affect Your MedTech Adoption Journey
November 25 2020
What is NICE Recommendation and Why is it Useful?
July 10 2020
What is MedTech Market Access?
June 04 2020
Planning Your Engagement Strategy with the NHS Post-Covid-19
June 04 2020
“Battle Stations”: MedTech Can Fight Against Unseen Enemies Like Covid-19
April 02 2020
MedTech Industry Engagement with NHS England after Covid-19
March 20 2020
New NHS England MedTech Funding Mandate Proposal – to get innovative medical devices, diagnostics and digital products to patients faster
November 16 2019
Innovative Approach That Gets Patients Back Into Their Own Homes After Hospital Stay Honoured - NHS England
July 25 2019
Health Technology Evaluation Methods
July 23 2019
NHS England Medical Device Reimbursement Opportunities
July 01 2019
NICE Guidance for High Performing MedTech Products an Accelerated Access Scheme
May 02 2019
IGES Institut GmbH Acquires Majority Shareholding in Device Access UK
March 04 2019
NICE Approves New Minimally Invasive Steam Ablation Treatment for Benign Prostatic Hyperplasia
August 21 2018
NHS England is Calling on the Best Innovators from Across the World to Apply to Join New NHS Adoption Scheme to Ensure Patients Benefit from New Technology Faster.
September 14 2018
Contact us